Cardarine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
=== Surgery === Surgery for back pain is typically used as a last resort, when serious neurological deficit is evident. A 2009 systematic review of back surgery studies found that, for certain diagnoses, surgery is moderately better than other common treatments, but the benefits of surgery often decline in the long term. Surgery may sometimes be appropriate for people with severe myelopathy or cauda equina syndrome. Causes of neurological deficits can include spinal disc herniation, spinal stenosis, degenerative disc disease, tumor, infection, and spinal hematomas, all of which can impinge on the nerve roots around the spinal cord. There are multiple surgical options to treat back pain, and these options vary depending on the cause of the pain. When a herniated disc is compressing the nerve roots, hemi- or partial-laminectomy or discectomy may be performed, in which the material compressing on the nerve is removed. A multi-level laminectomy can be done to widen the spinal canal in the case of spinal stenosis. A foraminotomy or foraminectomy may also be necessary, if the vertebrae are causing significant nerve root compression. A discectomy is performed when the intervertebral disc has herniated or torn. It involves removing the protruding disc, either a portion of it or all of it, that is placing pressure on the nerve root. Total disc replacement can also be performed, in which the source of the pain (the damaged disc) is removed and replaced, while maintaining spinal mobility.
== M == Maillard reaction Madelung synthesis Malaprade reaction, Periodic acid oxidation Malonic ester synthesis Mannich reaction Markó–Lam deoxygenation Markovnikov's rule, Markownikoff rule, Markownikow rule Marschalk reaction Martinet dioxindole synthesis McDougall monoprotection McFadyen–Stevens reaction McMurry reaction Meerwein arylation Meerwein–Ponndorf–Verley reduction Meisenheimer rearrangement Meissenheimer complex Menshutkin reaction Metal-ion-catalyzed σ-bond rearrangement Mesylation Merckwald asymmetric synthesis Metallo-ene reaction Methylation Meyer–Hartmann reaction Meyer reaction Meyer synthesis Meyer–Schuster rearrangement Michael addition Michael addition, Michael system Michael condensation Michaelis–Arbuzov reaction Midland Alpine borane reduction Mignonac reaction Milas hydroxylation of olefins Minisci reaction Mislow–Evans rearrangement Mitsunobu reaction Miyaura borylation Modified Wittig-Claisen tandem reaction Molisch's test Mozingo reduction Mukaiyama aldol addition (Mukaiyama reaction) Mukaiyama hydration Myers' asymmetric alkylation
== References == Anderson, G.B., (1999). "Epidemiological features of chronic low back pain". The Lancet (1) 354 Langevin, H.M., Bouffard, N.A., Badger, G.J., Churchill, D.L., Howe, A.K., (2006). "Subcutaneous tissue fibroblasts cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism". J Cell Physiol (3) 207 Langevin, H.M., Churchill, D.L., Cipolla, M.J., (2001). "Mechanical signalling through connective tissue: A mechanism for the therapeutic effect of acupuncture". FASEB J (1) 15
Pyridinoline, also known as Hydroxylysylpyridinoline, is a fluorescent cross-linking compound of collagen fibers. Crosslinks in collagen and elastin are derived from lysyl and hydroxylysyl residues, a process catalyzed by lysyl oxidase. Fujimoto and colleagues first described the isolation and characterization of a fluorescent material in bovine Achilles tendon collagen and termed it pyridinoline. It is reported to be present in collagen of bone and cartilage, but is absent in collagen of skin. It is not present in newly synthesized collagen and is formed from aldimine cross-links during maturation of collagen fibers. Pyridinoline and deoxypyridinoline were found to be released into the blood during bone degradation and rapidly excreted in the urine. In a preliminary study, both these compounds were proposed as a marker for metastatic bone tumor in patients with prostate cancer.
Radioactive isotopes that decay by pure electron capture can be inhibited from radioactive decay if they are fully ionized ("stripped" is sometimes used to describe such ions). It is hypothesized that such elements, if formed by the r-process in exploding supernovae, are ejected fully ionized and so do not undergo radioactive decay as long as they do not encounter electrons in outer space. Anomalies in elemental distributions are thought to be partly a result of this effect on electron capture. Inverse decays can also be induced by full ionisation; for instance, 163Ho decays into 163Dy by electron capture; however, a fully ionised 163Dy decays into a bound state of 163Ho by the process of bound-state β− decay. Chemical bonds can also affect the rate of electron capture to a small degree (in general, less than 1%) depending on the proximity of electrons to the nucleus. For example, in 7Be, a difference of 0.9% has been observed between half-lives in metallic and insulating environments. This relatively large effect is because beryllium is a small atom that employs valence electrons that are close to the nucleus, and also in orbitals with no orbital angular momentum. Electrons in s orbitals (regardless of shell or primary quantum number), have a probability antinode at the nucleus, and are thus far more subject to electron capture than p or d electrons, which have a probability node at the nucleus.
Sources: en.wikipedia.org
Brian Christian wrote that experts have pivoted "from the question of 'what they know' to the question of 'what they're doing with it'." Generative AI is often trained on unlicensed copyrighted works, including in domains such as images or computer code; the output is then used under the rationale of "fair use". Experts disagree about how well and under what circumstances this rationale will hold up in courts of law; relevant factors may include "the purpose and character of the use of the copyrighted work" and "the effect upon the potential market for the copyrighted work". Website owners can indicate that they do not want their content scraped via a "robots.txt" file. However, some companies will scrape content regardless because the robots.txt file has no real authority. In 2023, leading authors (including John Grisham and Jonathan Franzen) sued AI companies for using their work to train generative AI. Another discussed approach is to envision a separate sui generis system of protection for creations generated by AI to ensure fair attribution and compensation for human authors.
=== Monotreme research === Flannery et al. (2026) review the fossil record and evolutionary history of monotremes. Chimento (2026) reports evidence of similarities of morphology of teeth and mandibles of monotremes, meridiolestidans and dryolestoids from Northern Hemisphere, and interprets the available data as consistent with origin of monotreme dental pattern from teeth of Gondwanan dryolestoids. Ziegler & Lockett (2026) report the discovery of a skull of Megalibgwilia owenii from the Foul Air Cave in the Buchan Caves Reserve, representing the first record of the species from Victoria (Australia).
Winemakers can track the progression of malolactic fermentation by paper chromatography or with a spectrophotometer. The paper chromatography method involves using capillary tubes to add small samples of the wine to chromatograph paper. The paper is then rolled and placed in a jar filled with a butanol solution containing bromocresol green indicator dye for several hours. After the paper is pulled out and dried, the distance of yellow-colored "splotches" from the base line denotes the presence of various acids, with tartaric being closest to the baseline followed by citric, malic, and finally lactic acids near the top of the paper. A significant limitation to paper chromatography is that it will not show exactly how much malic is still remaining in the wine, with the size of the "splotch" on the paper having no correlation to a quantitative figure. The sensitivity of the paper is also limited to a detection threshold of 100–200 mg/L while most measurements of "MLF stability" target a malic level of less than 0.03 g/L (30 mg/L). The enzymatic method allows for a quantitative measurement of both malic and lactic acids, but requires the expense of reagent kits and a spectrophotometer that can measure absorbance values at 334, 340, or 365 nm.
== Background on native platelets == Native platelets play a vital role in hemostasis, the process of blood clotting and wound healing. Also known as thrombocytes, platelets are anucleate cell fragments derived from megakaryocytes in the bone marrow. Under healthy conditions, platelets circulate in an inactive state within the bloodstream and rapidly respond to vascular injury by initiating a complex cascade of coagulation events to prevent excessive blood loss. Native platelets are 2-3 micrometers in diameter and possess a highly specialized structure that enables their function in clot formation. Their cytoplasm contains dense granules and alpha granules, which store essential molecules such as adenosine diphosphate (ADP), serotonin, fibrinogen, and growth factors. These molecules are important for platelet activation, adhesion, and recruitment of additional platelets during vascular injury. The platelet membrane contains an abundance of glycoproteins, including integrins and receptors like glycoprotein Ib-IX-V and glycoprotein IIb/IIIa, which mediate interactions with the vascular endothelium and other platelets. A cytoskeleton composed of actin and tubulin allows platelets to change shape during activation, which extends filopodia to enhance adhesion and clot stability. Platelets engage in the following three-step process to form a stable blood clot: adhesion, activation, and aggregation.
== In popular culture == Stuntman and comedian Steve-O has publicly spoken of his involvement as a test subject in an early ractopamine study whose aim was to determine the stress limits of ractopamine saturation in humans. Glover says "Based on how dangerous the study was, the more money you get."
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.